论文部分内容阅读
CD34+造血细胞以其独特的生物学功能正成为造血调控、造血于细胞移植和基因治疗最理想的靶细胞。本文探讨人正常骨髓CD34+造血细胞在体外扩增形成单个核细胞（MNC）及粒单系集落形成单位（CFU－GM）的能力，采用CIMS－100新型免疫磁性无菌分离术可获得纯度＞90％的CD34+造血细胞，其直接形成CFLJ－GM的能力要较骨髓MNC提高的倍，并且在含EGIIS组合造血生长因子的无基质液培养系统中，CD34+造血细胞在四周内可持续扩增产生大量MNC及CFU－GM，最高分别可达1770倍和48倍，但不同个体问CD34+造血细胞的这种能力差别较大。上述结果提示，CD34+造血细胞在最佳组合HGFs的无基质液培养条件下，能扩增产生大量成熟及晚期造血祖细胞，可以适用于临床治疗的需求，
Because of its unique biological function, CD34 + hematopoietic cells are becoming the target of hematopoietic regulation and hematopoiesis, which are ideal for cell transplantation and gene therapy. In this paper, the ability of human normal bone marrow CD34 + hematopoietic cells to expand in vitro to form mononuclear cells (MNCs) and granulocyte colony forming units (CFU-GMs) was investigated in this study. The purity of the purified CD34 + % Of CD34 + hematopoietic cells, their ability to directly form CFLJ-GM is increased by a factor of two than that of bone marrow MNCs, and CD34 + hematopoietic cells proliferate sustainably within four weeks in a matrix-free fluid culture system containing EGIIS combined hematopoietic growth factors MNC and CFU-GM, the highest up to 1770 times and 48 times, but different individuals ask CD34 + hematopoietic cells of this ability vary greatly. These results suggest that CD34 + hematopoietic cells can proliferate to produce a large number of mature and late-stage hematopoietic progenitor cells in the optimal combination of HGFs without matrix-based liquid culture, which can be applied to the needs of clinical treatment,